These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 6268703)
21. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159 [TBL] [Abstract][Full Text] [Related]
22. Alteration in the level of endogenous hypothalamic prostaglandins induced by delta 9-tetrahydrocannabinol in the rat. Coupar IM; Taylor DA Br J Pharmacol; 1982 May; 76(1):115-9. PubMed ID: 6282371 [TBL] [Abstract][Full Text] [Related]
23. Confirmation of cannabis use. II. Determination of tetrahydrocannabinol metabolites in urine and plasma by HPLC with ECD. Nakahara Y; Sekine H; Cook CE J Anal Toxicol; 1989; 13(1):22-4. PubMed ID: 2540383 [TBL] [Abstract][Full Text] [Related]
24. Pharmacology of some synthetic tetrahydrocannabinols. Pradhan SN Neurosci Biobehav Rev; 1984; 8(3):369-85. PubMed ID: 6095152 [TBL] [Abstract][Full Text] [Related]
25. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Nov; 446():1-317. PubMed ID: 12594529 [TBL] [Abstract][Full Text] [Related]
26. One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors. Rosati O; Messina F; Pelosi A; Curini M; Petrucci V; Gertsch J; Chicca A Eur J Med Chem; 2014 Oct; 85():77-86. PubMed ID: 25072877 [TBL] [Abstract][Full Text] [Related]
27. Acute Δ-9-tetrahydrocannabinol administration in female rats attenuates immediate responses following losses but not multi-trial reinforcement learning from wins. Wong SA; Randolph SH; Ivan VE; Gruber AJ Behav Brain Res; 2017 Sep; 335():136-144. PubMed ID: 28811178 [TBL] [Abstract][Full Text] [Related]
28. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach. Awasthi R; An G; Donovan MD; Boles Ponto LL J Pharm Sci; 2018 Feb; 107(2):745-755. PubMed ID: 28942005 [TBL] [Abstract][Full Text] [Related]
29. Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol. Economidou D; Mattioli L; Ubaldi M; Lourdusamy A; Soverchia L; Hardiman G; Campolongo P; Cuomo V; Ciccocioppo R Toxicol Appl Pharmacol; 2007 Aug; 223(1):73-85. PubMed ID: 17618662 [TBL] [Abstract][Full Text] [Related]
30. Hexadeutero-11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid: a superior internal standard for the GC/MS analysis of delta 9-THC acid metabolite in biological specimens. elSohly MA; Little TL; Stanford DF J Anal Toxicol; 1992; 16(3):188-91. PubMed ID: 1326061 [TBL] [Abstract][Full Text] [Related]
31. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444 [TBL] [Abstract][Full Text] [Related]
32. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Darmani NA; Johnson JC Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052 [TBL] [Abstract][Full Text] [Related]
33. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146 [TBL] [Abstract][Full Text] [Related]
34. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. de Salas-Quiroga A; Díaz-Alonso J; García-Rincón D; Remmers F; Vega D; Gómez-Cañas M; Lutz B; Guzmán M; Galve-Roperh I Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13693-8. PubMed ID: 26460022 [TBL] [Abstract][Full Text] [Related]
35. Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin. Wei Q; Liu L; Cong Z; Wu X; Wang H; Qin C; Molina P; Chen Z J Neuroimmune Pharmacol; 2016 Sep; 11(3):584-591. PubMed ID: 27109234 [TBL] [Abstract][Full Text] [Related]
36. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Quinn HR; Matsumoto I; Callaghan PD; Long LE; Arnold JC; Gunasekaran N; Thompson MR; Dawson B; Mallet PE; Kashem MA; Matsuda-Matsumoto H; Iwazaki T; McGregor IS Neuropsychopharmacology; 2008 Apr; 33(5):1113-26. PubMed ID: 17581536 [TBL] [Abstract][Full Text] [Related]
37. Delta 9-tetrahydrocannabinol: elevation of absolute visual thresholds of rabbits. Rose SE; Dwyer WO; Yehle AL Pharmacol Biochem Behav; 1979 Jun; 10(6):851-3. PubMed ID: 482306 [TBL] [Abstract][Full Text] [Related]
38. A chronic low dose of Δ Bilkei-Gorzo A; Albayram O; Draffehn A; Michel K; Piyanova A; Oppenheimer H; Dvir-Ginzberg M; Rácz I; Ulas T; Imbeault S; Bab I; Schultze JL; Zimmer A Nat Med; 2017 Jun; 23(6):782-787. PubMed ID: 28481360 [TBL] [Abstract][Full Text] [Related]
39. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Muchtar S; Almog S; Torracca MT; Saettone MF; Benita S Ophthalmic Res; 1992; 24(3):142-9. PubMed ID: 1328979 [TBL] [Abstract][Full Text] [Related]
40. Effects of drugs on behavior in pigeons tolerant to delta 9-tetrahydrocannabinol. McMillan DE; Leander JD; Dudley KH J Pharmacol Exp Ther; 1980 Jan; 212(1):85-90. PubMed ID: 7351628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]